ATE456953T1 - Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga - Google Patents

Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga

Info

Publication number
ATE456953T1
ATE456953T1 AT06736552T AT06736552T ATE456953T1 AT E456953 T1 ATE456953 T1 AT E456953T1 AT 06736552 T AT06736552 T AT 06736552T AT 06736552 T AT06736552 T AT 06736552T AT E456953 T1 ATE456953 T1 AT E456953T1
Authority
AT
Austria
Prior art keywords
pyrimethamine
analogs
treatment
lateral sclerosis
amyotrophic lateral
Prior art date
Application number
AT06736552T
Other languages
German (de)
English (en)
Inventor
Sean Scott
Daniel Benjamin
Original Assignee
Alsgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alsgen Inc filed Critical Alsgen Inc
Application granted granted Critical
Publication of ATE456953T1 publication Critical patent/ATE456953T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyurethanes Or Polyureas (AREA)
AT06736552T 2005-03-04 2006-03-01 Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga ATE456953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65850505P 2005-03-04 2005-03-04
PCT/US2006/007257 WO2006096405A2 (en) 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues

Publications (1)

Publication Number Publication Date
ATE456953T1 true ATE456953T1 (de) 2010-02-15

Family

ID=36953835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736552T ATE456953T1 (de) 2005-03-04 2006-03-01 Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga

Country Status (10)

Country Link
US (1) US20060211645A1 (cg-RX-API-DMAC7.html)
EP (1) EP1917017B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008531710A (cg-RX-API-DMAC7.html)
CN (1) CN101184493A (cg-RX-API-DMAC7.html)
AT (1) ATE456953T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006220919A1 (cg-RX-API-DMAC7.html)
CA (1) CA2600067A1 (cg-RX-API-DMAC7.html)
DE (1) DE602006012115D1 (cg-RX-API-DMAC7.html)
ES (1) ES2340708T3 (cg-RX-API-DMAC7.html)
WO (1) WO2006096405A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101232888A (zh) * 2005-03-04 2008-07-30 阿尔斯根公司 用炔诺酮及其类似物治疗肌萎缩性侧索硬化
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006096415A2 (en) * 2005-03-04 2006-09-14 Alsgen, Llc Modulation of neurodegenerative diseases through the estrogen receptor
US20080153094A1 (en) * 2006-10-13 2008-06-26 Minor James M Reduction of nonspecific binding in nucleic acid assays and nucleic acid synthesis reactions
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
SI2718270T1 (sl) 2011-06-10 2022-11-30 Merck Patent Gmbh Sestavki in postopki za proizvodnjo pirimidinskih in piridinskih spojin z BTK inhibitorno aktivnostjo
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
KR20210056931A (ko) * 2019-11-11 2021-05-20 에스케이케미칼 주식회사 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US7442629B2 (en) * 2004-09-24 2008-10-28 President & Fellows Of Harvard College Femtosecond laser-induced formation of submicrometer spikes on a semiconductor substrate
KR101031720B1 (ko) * 2001-11-28 2011-04-29 비티지 인터내셔널 리미티드 질소함유 헤테로아릴 화합물을 함유하는 알츠하이머병의예방약 또는 치료약 또는 아밀로이드 단백질 섬유화억제제
KR20040099324A (ko) * 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN101232888A (zh) * 2005-03-04 2008-07-30 阿尔斯根公司 用炔诺酮及其类似物治疗肌萎缩性侧索硬化
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2006096405A2 (en) 2006-09-14
EP1917017B1 (en) 2010-02-03
AU2006220919A1 (en) 2006-09-14
WO2006096405A8 (en) 2008-04-10
JP2008531710A (ja) 2008-08-14
DE602006012115D1 (de) 2010-03-25
US20060211645A1 (en) 2006-09-21
EP1917017A2 (en) 2008-05-07
ES2340708T3 (es) 2010-06-08
WO2006096405A3 (en) 2007-05-18
CA2600067A1 (en) 2006-09-14
CN101184493A (zh) 2008-05-21

Similar Documents

Publication Publication Date Title
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200531689A (en) Therapeutic agents
WO2008067389A3 (en) Modulation of sod protein synthesis for the treatment of neurodegenerative diseases
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
TW200635903A (en) Therapeutic agents
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
TW200611695A (en) Pyrrolopyridine derivatives
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
ATE433966T1 (de) Methylendipiperidinderivate
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
TW200633986A (en) Therapeutic agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties